- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00587418
L-arginine for Prevention of Kidney Damage in Liver Transplant Recipients
L-arginine Supplement for the Prevention of Calcineurin Inhibitor Nephrotoxicity
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Although liver transplantation (LTx) is now well-established as a means of restoring health in patients with liver failure, there remain opportunities to further optimize its outcome. One of the major sources of mortality and morbidity in LTx recipients is renal insufficiency associated with nephrotoxicity of immunosuppressant agents, particularly calcineurin inhibitors (i.e., cyclosporine and tacrolimus). These agents are also associated with hypertension and diabetes among LTx recipients, contributing to further reduction in renal function. In a report based on nationwide data, 18% of LTx recipients developed renal failure within 5 years.
Most of the decline in renal function after LTx occurs in the first few months. This is in part because patients are exposed to the highest levels of calcineurin inhibitors in the early post-LTx period, when the risk of acute cellular rejection is the greatest. Calcineurin inhibitors produce intense renal vasoconstriction, which may be reversible early on. Over time, however, irreversible changes, such as vascular angiopathy, tubular atrophy and eventually interstitial fibrosis, contribute to permanent reduction in renal perfusion and glomerular filtration. Thus, interventions to preserve renal function after LTx would be most effective in the early post-LTx period, when most reduction in renal function occurs and when renal vascular changes are potentially reversible.
Existing evidence and our preliminary data indicate that impairment of vasodilatory response mediated by nitric oxide (NO) plays an important role in the pathogenesis of calcineurin inhibitor nephrotoxicity. Our overall hypothesis is that L-arginine supplement provides protection against calcineurin inhibitor nephrotoxicity. L-arginine, a naturally occurring amino acid, is the main substrate of the NO synthase enzyme and exogenous supplementation of L-arginine may improve renal perfusion by inducing renal vasodilation via increased NO production. Although L-arginine has been shown to prevent renal damage from calcineurin inhibitors in experimental animals, its efficacy in preserving renal function has not been studied in human LTx recipients.
In this application, we propose to conduct a pilot, randomized, double-blinded, placebo-controlled trial to explore the use of prophylactic L-arginine supplement in preserving renal function in LTx recipients. Twenty-four (24) LTx recipients recovering uneventfully from the procedure will be recruited for the study. Subjects will be randomized 1:1 to receive 9g per day of L-arginine or placebo given orally for 7 days between 14 and 21 days after LTx, followed by open-label maintenance with L-arginine. The aims of the study are as follows:
AIM 1. To determine the effect of oral L-arginine supplement on glomerular filtration rate in LTx recipients. We will compare changes in GFR, as estimated by the eGFRcys equation, before and after a 7-day trial of L-arginine versus placebo. The eGFRcys equation has recently been shown to be the most accurate GFR estimator incorporating serum cystatin-C and creatinine concentrations, age, gender and race.
AIM 2. To determine the effect of L-arginine supplement on secondary efficacy endpoints. We will compare plasma L-arginine concentrations and urinary cyclic-GMP, the latter being a key metabolite of renal NO, between the L-arginine and placebo groups.
AIM 3. To evaluate the safety of oral L-arginine supplement in liver transplant recipients. We will compare the frequency and severity of adverse events between the L-arginine and placebo groups.
AIM 4. To determine the effect of maintenance open label L-arginine on GFR. After the 7-day trial, participants will be offered an open label L-arginine for 13 additional weeks. We will compare their GFR determined by iothalamate clearance before and after the maintenance use of L-arginine supplement.
Our hypothesis is that L-arginine will promote the release of NO in the renal vascular bed, increasing renal blood flow and glomerular filtration rate (AIM 1). We believe it is critical that we test this in patients early after LTx before irreversible vascular and glomerular damage is established. Once this proof of concept is attained, we would like to link the observation with plasma L-arginine concentration and urinary c-GMP excretion (AIM 2). Based on extensive experience at Mayo Clinic of using oral L-arginine, we expect to demonstrate no clinically significant adverse events with L-arginine (AIM 3). The data from the open label maintenance phase (AIM 4) will help gauge whether the short term benefit shown in AIM 1 is sustainable for a longer time frame.
The significance of these studies is based on several factors: (1) Calcineurin inhibitor-induced renal insufficiency is a major source of morbidity and mortality among LTx recipients; (2) Once it is established, there is no effective treatment for calcineurin inhibitor-induced renal insufficiency; and (3) If the results of this study support our hypothesis, we will be able to embark upon a full scale, randomized trial of long-term oral L-arginine supplement using GFR as the end point. Such a study will be able to answer whether a simple amino acid supplement may prevent calcineurin inhibitor nephrotoxicity, making a fundamental difference in morbidity, mortality and quality of life of our patients, who have undergone a life-changing procedure, namely liver transplantation.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria
- Informed written consent
- Ages 18+ at the time of entry into the study
- Recipient of primary liver transplantation from a deceased or live donor
Stable with satisfactory allograft function
- Total bilirubin < 2.5 mg/dl and
- Aminotransferase < x 3 upper limit of normal (e.g., ALT<120 IU/mL)
- Serum creatinine < 2.5 mg/dl without dialysis
- Maintenance immunosuppression including tacrolimus or cyclosporine
Stable hemodynamic function
- Systolic blood pressure > 100 mmHg
- Resting pulse rate < 100
Exclusion criteria
- Recipient of combined liver-kidney transplantation
- Prior organ transplantation (i.e., exposure to calcineurin inhibitors)
- Established primary renal disease with active urinary sediments
- On-going renal replacement therapy
- Pulmonary hypertension (e.g., portopulmonary hypertension)
- Iodine allergy
- Other systemic illness (e.g., infection) that require hospitalization care beyond 2 weeks after LTx
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo powder 9.2g bid for 7 days
|
Experimental: Arginine
|
Arginaid (Novartis) 1 package (9.2g) bid for 7 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in eGFR before and after L-arginine
Time Frame: 7 days with option for 12 week maintenance phase
|
7 days with option for 12 week maintenance phase
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Urinary excretion of cGMP before and after L-arginine. Creatinine before and after L-arginine.
Time Frame: 7 days with option for 12 week maintenance phase
|
7 days with option for 12 week maintenance phase
|
Safety of oral L-arginine
Time Frame: 7 days with option for 12 week maintenance phase
|
7 days with option for 12 week maintenance phase
|
Change in iothalamate clearance before and after optional 12 week maintenance open label phase.
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: W. Ray Kim, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 06-007047
- R21AT004174 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Transplant Recipients
-
University of CincinnatiUniversity of Colorado, Denver; Children's Hospital Medical Center, CincinnatiCompletedLiver Transplant Recipients | Kidney Transplant RecipientsUnited States
-
Ege UniversityCompletedLiver Transplant RecipientsTurkey
-
Icahn School of Medicine at Mount SinaiCompleted
-
Baylor Research InstituteUnknown
-
National Institute of Allergy and Infectious Diseases...Clinical Trials in Organ TransplantationCompletedLiver Transplantation | Liver Transplant RecipientsUnited States
-
National Institute of Allergy and Infectious Diseases...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Immune...CompletedLiver Transplantation | Immunosuppression | Liver Transplant RecipientsUnited States, Canada
-
Icahn School of Medicine at Mount SinaiUniversity of California, Los Angeles; University of Pittsburgh; Children's Hospital... and other collaboratorsCompletedTacrolimus | Nonadherence | Pediatric Liver Transplant RecipientsUnited States
-
Icahn School of Medicine at Mount SinaiNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University... and other collaboratorsCompletedPediatric Recipients of a Liver TransplantUnited States
-
National Institute of Allergy and Infectious Diseases...Johns Hopkins University; PPDActive, not recruitingLiver Transplant Recipients | Kidney Transplant RecipientsUnited States
-
Methodist HealthcareCompletedRecipients of Liver TransplantUnited States
Clinical Trials on L-arginine
-
Emory UniversityNational Center for Complementary and Integrative Health (NCCIH); Children's...CompletedSickle Cell Disease | Vaso-occlusive Pain EpisodeUnited States
-
Juliano CasonattoUnknown
-
Instituto de Oncología Ángel H. RoffoCompletedUnresectable Multiple Brain Metastases
-
University Hospital, Strasbourg, FranceCompletedSkeletal Muscle Ischemia | Severe Lower Limb Ischemia | Mitochondrial DysfunctionFrance
-
UCSF Benioff Children's Hospital OaklandCompletedVaso-occlusive Pain EpisodesUnited States
-
Hospital Civil de GuadalajaraNot yet recruitingArginine + Citrulline as a Supplement for Weight Gain in Fetus With a Decrease in Their Growth CurveFetal Growth Retardation
-
Alexandra Hospital, Athens, GreeceUniversity of AthensUnknown
-
Maastricht University Medical CenterNovartis Medical NutritionCompletedSepsis | Septic Shock
-
Centro Universitario de TonaláWithdrawn
-
Emory UniversityRecruiting